521 reports of this reaction
2.6% of all NADOLOL reports
#6 most reported adverse reaction
FATIGUE is the #6 most commonly reported adverse reaction for NADOLOL, manufactured by Alembic Pharmaceuticals Inc.. There are 521 FDA adverse event reports linking NADOLOL to FATIGUE. This represents approximately 2.6% of all 20,171 adverse event reports for this drug.
Patients taking NADOLOL who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for NADOLOL, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for NADOLOL:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 521 FDA reports for NADOLOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.6% of all adverse event reports for NADOLOL, making it a notable side effect.
If you experience fatigue while taking NADOLOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.